Finoriq research workspace

AGIOS PHARMACEUTICALS, INC. (AGIO) Historical Metrics

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the. Review AGIO valuation ratios, fundamentals, and filing metrics on Finoriq.

Company Snapshot

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Company

AGIOS PHARMACEUTICALS, INC. (AGIO)

Ticker

AGIO

Market Cap

$2.4B

Latest Price

$40.25

Industry

Biotech & Pharma

Open insider transactions

AGIOS PHARMACEUTICALS, INC. (AGIO) Current Valuation Metrics

Static valuation preview for AGIOS PHARMACEUTICALS, INC. (AGIO). Market data retrieved 2026-07-08. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.